articl
provid
summari
invit
lectur
intern
confer
antivir
research
sponsor
intern
societi
antivir
research
isar
held
san
francisco
california
may
report
begin
synopsi
symposium
held
memori
late
toni
follow
brief
summari
lectur
recipi
isar
two
major
award
keynot
address
plenari
lectur
clinic
symposium
two
chemistri
minisymposia
paper
simpli
provid
overview
oral
present
accompani
refer
scientif
literatur
descript
favor
treatment
outcom
taken
recommend
clinic
use
erik
de
clercq
rega
institut
medic
research
leuven
belgium
fig
erik
describ
first
meet
toni
symposium
synthesi
nucleosid
nucleotid
polynucleotid
may
germani
felt
place
privileg
md
present
among
mani
phd
chemist
similarli
erik
found
mani
chemist
nato
meet
meet
il
ciocco
itali
may
regard
model
icar
meet
photograph
attende
meet
includ
isar
news
toni
becam
regular
attende
icar
meet
toni
first
clinic
success
duvira
gel
licens
czechoslovakia
herp
labiali
see
john
martin
present
phosphon
compound
hpmpa
toxic
progress
clinic
use
first
long
seri
compound
cidofovir
hpmpc
use
treat
herpesviru
infect
mainli
cytomegaloviru
cmv
resist
firstlin
therapi
occur
adefovir
dipivoxil
adv
licens
treat
hepat
b
one
drug
stand
except
tenofovir
oral
prodrug
approv
hiv
therapi
combin
emtricitabin
ftc
truvada
approv
atripla
combin
truvada
efavirenz
approv
complera
usa
eviplera
europ
approv
quad
pill
stribild
contain
truvada
elvitegravir
cobicistat
approv
usa
europ
singletablet
regimen
contain
tenofovir
key
compon
transform
hiv
therapi
give
patient
mani
year
nearnorm
life
visit
toni
olomouc
czechoslovakia
erik
notic
unescoclassifi
monument
dedic
holi
triniti
stimul
erik
think
one
team
toni
chemist
erik
md
john
martin
also
chemist
gilead
long
close
collabor
among
three
enabl
tenofovir
becom
lifesav
therapi
seem
erik
john
part
differ
triniti
triniti
erik
show
sever
photograph
triniti
variou
exot
locat
includ
rio
grand
gorg
new
mexico
icar
meet
santa
fe
fig
john
martin
present
toni
erik
plaqu
recognit
gilead
scienc
campaign
promot
czech
success
toni
featur
display
pragu
airport
call
vaclav
havel
airport
toni
consid
lead
scientist
czech
republ
truvada
approv
prophylact
use
prevent
spread
hiv
day
toni
die
juli
john
martin
gilead
scienc
foster
citi
ca
usa
fig
john
may
recogn
part
triniti
fortun
next
speaker
like
toni
erik
john
long
close
associ
isar
toni
born
synthes
first
nucleotid
dhpa
publish
scienc
approv
czechoslovakia
duvira
gel
first
phosphon
hpmpa
publish
natur
although
compound
progress
clinic
drug
led
cidofovir
approv
treatment
cmv
retin
aid
patient
adefovir
pmea
approv
therapi
hepat
b
ultim
tenofovir
becom
major
success
treat
hivinfect
patient
first
introduct
market
share
increas
well
triniti
start
think
singlepil
regimen
led
atripla
approv
complera
stribild
triniti
anoth
major
success
enabl
hivinfect
patient
anywher
treat
tenofovir
expand
access
program
establish
gilead
toni
erik
waiv
royalti
sale
countri
poor
access
health
care
tenofovir
variou
form
avail
countri
distribut
wide
known
hivinfect
patient
thought
improv
access
effect
therapi
contribut
mark
reduct
hiv
transmiss
least
part
due
peopl
will
test
hiv
know
good
therapi
avail
john
end
tribut
show
photograph
toni
birthday
latter
pragu
robert
schooley
univers
california
san
diego
ca
usa
intersci
confer
antimicrobi
agent
chemotherapi
icaac
san
francisco
ca
usa
first
result
report
studi
threedrug
combin
contain
tenofovir
tdf
treatment
hivinfect
patient
tdf
compar
combin
efficaci
fewer
side
effect
compar
azt
tdf
efficaci
better
safeti
profil
week
therapi
gave
mark
side
effect
especi
mitochondri
toxic
featur
treatment
tdf
note
next
step
combin
tdf
emtricitabin
ftc
known
truvada
licens
groundbreak
move
gilead
bm
cooper
simplifi
hiv
therapi
combin
three
drug
singl
pill
truvada
efavirenz
form
singl
onceaday
pill
atripla
licens
tenofovir
use
worldwid
treat
million
hivinfect
patient
hiv
patient
receiv
antiretrovir
therapi
mani
part
expand
access
develop
countri
exampl
impact
initi
life
expect
increas
ten
year
region
rural
subsaharan
africa
patient
take
tenofovir
year
robert
grant
univers
california
san
francisco
ca
usa
clear
need
prevent
hiv
transmiss
even
recent
million
new
hivinfect
peopl
per
year
worldwid
young
adult
usa
rate
new
infect
remain
year
sinc
part
continu
mani
new
infect
half
new
transmiss
happen
acut
phase
hiv
infect
patient
know
hivinfect
statu
also
mani
patient
suppress
therapi
one
best
place
therapi
san
francisco
minor
hivinfect
peopl
therapi
wherea
averag
usa
even
less
prevent
attempt
start
therapi
either
prior
exposur
prep
post
exposur
within
h
clinic
sign
pep
truvada
ftctdf
evalu
oncedaili
dose
good
degre
forgiv
miss
dose
drug
resist
may
occur
rare
high
cost
viral
replic
capac
clinic
trial
prophylact
dose
prep
reveal
mani
problem
mainli
due
poor
adher
men
sex
men
msm
better
efficaci
women
adher
rate
women
low
one
factor
may
long
consent
form
includ
page
potenti
side
effect
mani
miss
dose
intentiontotreat
analys
becom
rather
meaningless
analys
focus
outcom
rel
amount
drug
taken
new
infect
subject
detect
drug
contrast
seem
seroconvers
subject
take
drug
daili
compar
subject
take
tablet
per
week
risk
transmiss
increas
fewer
dose
per
week
even
two
dose
per
week
gave
slight
reduct
transmiss
risk
factor
emerg
trial
trial
period
trend
toward
safer
sex
increas
condom
use
oral
truvada
ftctdf
appear
well
toler
clinic
side
effect
report
subject
gener
seen
first
week
resolv
still
therapi
detect
case
drug
resist
tdf
resist
ftc
two
case
alreadi
infect
baselin
import
conclus
work
prophylact
therapi
may
help
destigmat
therapi
prep
progress
openlabel
studi
henri
chan
chines
univers
hong
kong
hepat
b
natur
slowli
progress
diseas
lead
death
year
drug
efficaci
judg
reduct
viral
load
time
taken
drug
resist
appear
ever
sinc
introduct
lamivudin
hepat
b
therapi
improv
adefovir
dipivoxil
adv
gave
better
control
viral
load
previou
therapi
year
patient
undetect
hbv
level
resist
present
patient
adv
realli
activ
enough
nearli
patient
achiev
viral
suppress
tenofovir
tdf
therapi
still
resist
year
year
patient
liver
biopsi
show
patient
improv
fibrosi
score
unit
patient
worsen
substanti
efficaci
seen
reduc
liver
fibrosi
tdf
intern
accept
firstlin
therapi
hepat
b
recent
guidelin
includ
option
monotherapi
tdf
howev
advresist
hbv
remain
problem
patient
respond
well
tdf
richard
whitley
univers
alabama
birmingham
al
usa
three
decad
acyclovir
acv
mainstay
treatment
herp
simplex
viru
hsv
type
infect
newborn
current
follow
treatment
acut
diseas
thricedaili
acv
therapi
often
continu
month
futur
option
consid
use
valacyclovir
vacv
year
combin
acv
therapi
prodrug
cidofovir
investig
use
pcr
give
inform
viru
level
birth
cytomegaloviru
cmv
infect
ganciclovir
gcv
drug
choic
although
dose
reduct
often
need
due
safeti
concern
investig
pharmacokinet
valganciclovir
vgcv
newborn
areaunderth
curv
auc
drug
plasma
concentr
much
reduc
day
compar
day
newborn
renal
function
increas
rapidli
age
therefor
drug
dose
adjust
give
similar
auc
valu
day
phase
ii
trial
fulli
accru
compar
vgcv
either
week
month
data
expect
june
futur
combin
therapi
may
investig
drug
current
phase
ii
trial
prevent
cmv
diseas
transplant
patient
show
promis
clinic
trial
patient
adenoviru
andor
cytomegaloviru
infect
progress
includ
present
toma
cihlar
gilead
scienc
foster
citi
ca
usa
period
decad
includ
approv
therapi
aris
toni
initi
work
phosphon
includ
agent
treatment
infect
hiv
hepat
b
herpesvirus
discuss
futur
opportun
includ
new
drug
develop
hiv
hbv
dna
virus
hiv
infect
new
prodrug
tenofovir
tfv
tenofovir
alafenamid
taf
current
phase
iii
develop
comparison
tdf
taf
deliv
higher
level
tfv
diphosph
pbmc
much
lower
dose
taf
test
part
new
singl
tablet
regimen
contain
taf
ftc
elvitegravir
pharmacoenhanc
cobicistat
phase
ii
efficaci
combin
similar
recent
approv
stribild
trend
toward
less
impact
bone
renal
paramet
phospholipidbas
prodrug
tfv
current
phase
healthi
subject
show
promis
level
parent
tfv
activ
metabolit
pbmc
taf
also
test
treatment
chronic
hbv
infect
phase
ib
dose
escal
studi
mg
taf
recent
complet
data
analysi
progress
dipivoxil
prodrug
novel
guanin
nucleosid
phosphon
demonstr
potent
antihbv
efficaci
phase
ii
studi
dose
mg
exampl
novel
antivir
clinic
applic
nucleosid
phosphon
control
herpesviru
infect
includ
potent
phospholipid
prodrug
cidofovir
test
prophylaxi
treatment
variou
dna
viru
infect
mainli
cmv
adenoviru
unlik
parent
drug
cidofovir
administ
oral
exhibit
substanti
improv
safeti
profil
parent
compound
mg
twice
weekli
test
phase
iii
trial
immunocompromis
patient
recent
describ
antiherpesviru
activ
tenofovir
also
discuss
although
tenofovir
much
less
activ
hsv
hiv
clinic
data
suggest
use
topic
gel
give
suffici
high
drug
level
reduc
transmiss
tenofovir
topic
gel
test
prophylaxi
transmiss
larg
phase
iii
studi
current
progress
africa
target
rna
virus
nucleosid
phosphon
remain
major
challeng
sever
exampl
potenti
addit
applic
nucleosid
phosphon
beyond
antivir
therapi
mention
new
phosphon
good
activ
cell
cultur
plasmodium
malaria
pathogen
addit
prodrug
pmeg
advanc
stage
develop
applic
veterinari
oncolog
end
present
toma
announc
establish
new
isar
award
medicin
chemistri
memori
toni
first
award
present
icar
raleigh
north
carolina
usa
awarde
receiv
commemor
plaqu
monetari
award
opportun
present
lectur
icar
research
work
nomine
must
senior
scientist
intern
statur
medicin
chemistri
made
innov
contribut
impact
antivir
drug
discoveri
andor
develop
masanori
baba
kagoshima
univers
kagoshima
japan
fig
masanori
open
lectur
thank
great
professor
shiro
shigeta
erik
de
clercq
graduat
fukushima
medic
colleg
enter
graduat
school
medic
scienc
initi
studi
fukushima
varicella
zoster
viru
vzv
soon
collabor
erik
discov
potent
activ
bvdu
bvara
u
vzv
led
time
postdoc
leuven
close
colleagu
rudi
pauwel
jan
balzarini
dominiqu
schol
group
investig
hiv
activ
new
class
compound
phosphonyl
purin
deriv
first
paper
includ
toni
coauthor
discov
antihiv
activ
pmea
adefovir
follow
later
pmpa
tenofovir
group
develop
rapid
effici
assay
test
compound
paper
rapid
autom
tetrazoliumbas
colorimetr
assay
detect
test
compound
led
surpris
discoveri
uracil
deriv
hept
good
activ
total
inact
compound
shown
inhibitor
revers
transcriptas
rt
alloster
mode
action
number
hept
deriv
synthes
mistubishi
chemic
corp
japan
optim
compound
emivirin
develop
triangl
pharmaceut
usa
develop
halt
compar
emivirin
abacavir
phase
iii
trial
masanori
return
fukushima
move
kagoshima
univers
three
project
produc
interest
result
discoveri
develop
inhibitor
activ
identif
festinavir
novel
nucleosid
rt
inhibitor
discoveri
develop
biodegrad
nanoparticl
np
effici
antigencarri
capac
give
potent
adjuv
activ
collabor
takeda
pharmaceut
co
two
inhibitor
cenicriviroc
fig
discov
phase
iib
phase
clinic
trial
respect
cell
cultur
mutant
resist
cenicriviroc
obtain
cultiv
pbmc
week
mutant
viru
crossresist
cultiv
week
resist
hiv
obtain
icar
hiroaki
mitsuya
includ
summari
progress
festinavir
fig
keynot
lectur
vere
hodg
nucleosid
analog
first
develop
yale
univers
licens
japan
oncoli
biopharma
carri
phase
iia
trial
develop
bristolmy
squibb
masanori
show
result
doserang
studi
mg
vs
placebo
daili
dose
appear
dose
respons
highest
dose
reduc
viral
load
quickli
end
treatment
period
log
reduct
rna
festinavir
two
import
attribut
good
activ
mani
strain
resist
rt
inhibitor
triphosph
inact
human
dna
polymeras
professor
akashi
osaka
univers
group
investig
potenti
biodegrad
nanoparticl
np
adjuv
hydrophob
amino
acid
attach
biodegrad
polym
poli
cglutam
acid
hydrophob
interact
lead
format
np
protein
either
encapsul
within
np
immobil
surfac
dendrit
cell
take
npassoci
antigen
much
effici
antigen
alon
exampl
administ
mice
intranas
shown
promot
strong
cellular
immun
respons
summar
progress
far
antigennp
taken
dendrit
cell
also
induc
matur
mice
induc
potent
cellular
humor
immun
np
antigen
appear
safer
alum
experiment
adjuv
hope
np
great
potenti
use
antivir
anticanc
vaccin
largescal
synthesi
safeti
studi
ongo
william
prusoff
young
investig
award
lectur
irrat
ration
antivir
drug
design
andrea
brancal
cardiff
univers
cardiff
wale
uk
fig
andrea
began
lectur
refer
paper
entitl
synthesi
biolog
properti
iododeoxyuridin
analog
thymidin
william
prusoff
discoveri
bicycl
nucleic
acid
bcna
certainli
good
exampl
irrat
drug
design
key
step
depend
uk
royal
mail
belgian
postal
servic
nucleosid
analog
activ
hsv
appar
activ
vzv
ec
lm
repeat
test
show
compound
inact
postal
servic
ineffici
convert
nucleosid
bicycl
compound
convers
actual
potent
inhibitor
vzv
ec
lm
work
led
progress
phase
ii
trial
attempt
ration
discoveri
nucleosid
analog
good
inhibitor
hepat
c
viru
hcv
andrea
start
model
hcv
polymeras
howev
pol
one
player
nucleosid
long
path
drug
activ
triphosph
clearli
would
use
global
model
includ
enzym
typic
involv
nucleosid
activ
inactiv
naomi
born
enzym
involv
well
character
sever
crystal
structur
known
plenti
data
substrat
inhibitor
aim
predict
activ
metabol
pathway
fulli
autom
give
clear
output
fast
accur
possibl
current
naomi
enzym
accuraci
model
enzym
improv
train
known
set
compound
make
adjust
ment
fit
experiment
data
exampl
possibl
output
shown
ribavirin
triphosph
show
enzym
play
role
progress
far
naomi
fast
good
accuraci
fulli
autom
question
remain
enzym
includ
compound
substrat
inhibitor
anoth
potenti
hcv
target
helicas
nucleosidetp
bind
site
long
channel
hold
dsrna
possibl
alloster
site
difficult
predict
structur
small
molecul
would
bind
strongli
long
channel
ligbuild
produc
compound
fig
larg
number
chiral
center
make
impract
molecul
synthes
chemist
recogn
pattern
enabl
simpler
compound
design
case
first
compound
made
activ
ec
lm
next
step
forward
link
comput
joystick
point
devic
allow
oper
control
posit
molecul
molecul
approach
enzym
comput
calcul
forc
molecul
enzym
quickli
feed
back
joystick
anoth
exampl
computeraid
design
protein
thought
good
target
inhibit
chikungunya
viru
chikv
arboviru
replic
crystal
structur
known
model
built
use
venezuelan
equin
enceph
viru
veev
model
use
screen
zinc
databas
contain
million
compound
best
compound
evalu
biolog
one
activ
select
ec
lm
cc
lm
stage
crystal
structur
chikv
becam
avail
model
prove
accur
sar
studi
led
better
compound
ec
lm
cc
lm
conclus
human
input
remain
key
part
computeraid
design
keynot
address
know
thine
enemi
use
virolog
immunolog
develop
multifacet
approach
dengu
antivir
eva
harri
univers
california
berkeley
ca
usa
fig
dengu
viru
four
serotyp
includ
sever
genotyp
subdivid
clade
estim
million
peopl
becom
ill
year
fortun
rare
thousand
case
infect
develop
rapidli
progress
diseas
often
fatal
mani
peopl
possibl
million
becom
infect
symptom
import
previou
infect
give
protect
later
infect
strain
enhanc
diseas
progress
differ
strain
understand
reason
vital
develop
safe
dengu
vaccin
denv
two
mechan
entri
cell
via
receptor
attach
via
antibodi
latter
mechan
explain
previou
infect
enhanc
diseas
progress
instead
antibodi
bind
virion
lead
inactiv
bound
antibodi
give
viru
addit
rout
fc
receptorbear
target
cell
mous
model
use
minim
adapt
denv
serotyp
caus
selflimit
diseas
mice
transfer
antibodi
alon
mediat
lethal
diseas
known
antibodydepend
enhanc
ade
viral
load
increas
fusion
loop
antibodi
crossreact
serotyp
singl
mutat
specif
introduc
mutat
monoclon
antibodi
lose
glycosyl
site
disabl
abil
bind
cellular
receptor
mous
model
disabl
antibodi
nonfcrbind
mab
inhibit
ade
approach
may
abl
prevent
common
rel
mild
diseas
due
denv
would
great
advanc
abl
prevent
progress
seriou
often
fatal
diseas
associ
ade
plenari
address
rna
synthesi
cap
repair
rna
virus
novel
target
drug
design
bruno
canard
harvard
medic
school
boston
usa
plenari
present
bruno
review
crucial
role
play
noncod
region
end
genom
rna
replic
rna
virus
prevent
cellular
nucleas
degrad
viral
genom
rna
allow
viral
rna
bind
host
ribosom
viru
acquir
cap
essenti
done
one
three
way
creat
cap
use
viral
enzym
steal
cap
host
rna
molecul
use
host
cap
process
nucleu
strategi
adopt
differ
virus
initi
step
synthes
viral
rna
call
prime
involv
polymeras
repeatedli
ad
nucleotid
leav
templat
start
mani
time
refer
distribut
synthesi
prime
process
polymeras
creat
long
viral
rna
flaviviru
genom
end
highli
conserv
noncod
region
end
gaghairpinregion
part
highli
conserv
input
viru
mutat
exampl
ag
gg
output
viru
revert
ag
similarli
dengu
virus
conserv
ag
polymeras
seem
abl
creat
ag
without
templat
flavivirus
cap
enzym
exampl
protein
methyltransferas
domain
abl
catalyz
two
type
methyl
guanin
ome
adenin
coronavirus
far
longest
genom
base
rna
virus
virus
genom
base
like
flavivirus
coronavirus
viral
enzym
involv
make
cap
exampl
protein
omethyltransferas
activ
surprisingli
correspond
protein
sar
coronaviru
seem
correct
sequenc
cap
enzym
activ
vitro
howev
form
complex
give
enzymat
activ
also
complex
act
effici
exonucleas
correct
cap
mismatch
coronaviru
polymeras
form
complex
proofread
abil
presum
coronavirus
evolv
capabl
enabl
much
larger
genom
rna
virus
hetal
kocinski
achillion
pharmaceut
inc
new
ct
usa
sovaprevir
hcv
proteas
inhibitor
pi
pharmacokinet
studi
pk
show
drug
target
liver
boost
ritonavir
need
doseescal
phase
studi
dose
mg
well
toler
singl
multipl
dose
oncedaili
dose
day
gave
reduct
hcv
rna
load
log
dose
phase
iia
trial
sovaprevir
mg
daili
administ
ribavirin
rbv
compar
placebo
day
dose
activ
viral
load
reduc
log
day
littl
dose
respons
week
sustain
viral
respons
svr
without
real
dose
respons
sovaprevir
appear
retain
activ
strain
resist
previou
pi
elev
alt
level
mg
dose
revers
still
drug
develop
continu
mg
dose
inhibitor
viral
protein
known
enzymat
activ
domain
bind
viral
rna
domain
guid
viral
assembl
phase
pk
studi
evalu
dose
mg
mg
long
plasma
halflif
h
day
activ
genotyp
strain
resist
earlier
inhibitor
appear
high
genet
barrier
resist
singl
dose
mg
gave
log
reduct
viral
load
real
dose
respons
phase
iia
trial
n
administ
rbv
drug
long
load
dose
mg
given
day
mg
given
daili
thereaft
endpoint
sustain
viral
respons
week
svr
svr
two
patient
multipl
resist
mutat
earlier
drug
still
respond
svr
svr
respect
patient
loss
detect
viru
week
viral
breakthrough
one
patient
relaps
therapi
put
dual
therapi
combin
sovaprevir
also
investig
chang
pk
combin
either
fed
fast
subject
three
segment
phase
iia
studi
segment
sovaprevir
mg
combin
mg
load
dose
mg
mainten
dose
rbv
vs
placebo
control
segment
except
mg
sovaprevir
use
segment
placebo
previous
offer
activ
therapi
far
patient
receiv
trial
ongo
ami
patick
patick
pharmaceut
consult
behalf
santari
pharma
san
diego
ca
usa
within
utr
hcv
two
sixnucleotid
region
known
seed
site
site
highli
conserv
genotyp
hcv
bind
host
microrna
present
liver
cell
interact
prevent
degrad
viral
rna
therebi
enabl
hcv
replic
miravirsen
oligonucleotid
contain
block
base
cc
att
g
tca
ca
ct
c
bind
prevent
bind
viral
rna
cell
cultur
miravirsen
activ
genotyp
hcv
retain
activ
expect
resist
strain
direct
act
antihcv
drug
test
investig
resist
use
telaprevir
posit
control
mani
resist
coloni
present
day
telaprevir
miravirsen
lm
coloni
present
day
none
sequenc
far
mutat
chimpanze
studi
miravirsen
mg
weekli
week
gave
log
reduct
viral
load
mg
dose
earli
phase
phase
iia
studi
complet
pk
studi
confirm
dosedepend
plasma
liver
level
safeti
issu
expect
prolong
cholesterol
reduct
via
known
effect
fatti
acid
metabol
proofofconcept
studi
patient
genotyp
chronic
hcv
infect
treat
miravirsen
mg
given
weekli
week
dose
patient
follow
week
clear
dose
respons
dose
reduct
viral
load
continu
week
mg
dose
mean
reduct
viral
load
log
patient
becam
hcv
rna
undetect
treatment
well
toler
bind
region
hcv
rna
everi
patient
sequenc
baselin
week
week
viru
level
risen
nadir
signific
chang
detect
bind
region
ie
exclud
baselin
trial
combin
antivir
compound
plan
role
nucleosid
analog
treatment
chronic
hepat
c
john
fri
alio
biopharma
inc
south
san
francisco
ca
usa
uridin
nucleotid
analog
show
good
antihcv
activ
good
select
oral
prodrug
singl
diastereoisom
insid
cell
activ
form
triphosph
analog
act
chain
termin
h
long
enough
allow
daili
dose
took
passag
cell
cultur
month
obtain
resist
mutant
give
shift
ec
valu
mitochondri
protein
synthesi
test
inact
lm
evalu
phase
ascendingdos
trial
mg
decid
test
dose
mg
phase
ia
trial
treatment
patient
n
hcv
genotyp
dose
daili
day
lower
limit
quantit
lloq
iuml
limit
detect
lod
iuml
top
dose
reduct
viral
load
log
reach
lloq
one
reach
lod
patient
return
baselin
day
well
toler
patient
discontinu
therapi
dose
reduct
minor
advers
event
headach
diarrhea
fatigu
similar
phase
ia
trial
mg
given
rbv
reduct
viral
load
log
patient
reach
lloq
two
reach
lod
similar
trial
patient
genotyp
appear
respond
similarli
genotyp
futur
plan
includ
test
bristolmy
squibb
inhibitor
daclatasvir
initi
patient
genotyp
extend
patient
genotyp
second
half
pend
data
initi
studi
cenicriviroc
novel
oncedaili
potent
dual
antagonist
investig
treatment
hiv
infect
eric
lefebvr
tobira
therapeut
south
san
francisco
ca
usa
discoveri
structur
cenicriviroc
cvc
includ
elion
award
lectur
see
receptor
antagonist
nm
concentr
present
mainli
monocyt
receptor
hiv
patient
involv
monocyterel
immun
activ
plasma
h
daili
dose
cvc
possibl
phase
iib
trial
cvc
mg
compar
efv
treatment
arm
open
label
truvada
randomis
respect
patient
hiv
primari
object
compar
efficaci
safeti
cvc
efv
week
trial
continu
week
result
week
report
present
proport
patient
achiev
viru
control
hiv
rna
copiesml
respect
test
shift
viral
tropism
necessari
hiv
rna
level
least
copiesml
case
mg
cvc
group
respect
one
patient
tropism
shift
cvc
well
toler
proport
grade
advers
event
respect
discontinu
lipid
cholesterol
level
cvc
group
efv
group
use
marker
activ
monocyt
level
cvc
group
rais
efv
group
pk
studi
investig
drugdrug
interact
studi
design
administ
cvc
daili
day
add
drug
day
take
sampl
pk
analysi
day
boost
pi
ritonavir
areaunderthecurv
auc
cvc
increas
similar
studi
investig
interact
cvc
efv
cvc
effect
efv
level
efv
reduc
auc
cvc
dosag
adjust
would
necessari
problem
cvc
includ
combin
pill
look
futur
phase
ii
week
data
expect
juli
phase
iii
trial
plan
star
studi
singl
tablet
regimen
rilpivirineemtricitabin
tenofovir
df
noninferior
efavirenzemtricitabinetenofovir
df
adult
damian
mccoll
gilead
scienc
foster
citi
ca
usa
introduct
singletablet
daili
regimen
greatli
improv
hivinfect
patient
live
star
studi
first
compar
two
regimen
patient
take
one
tablet
daili
two
regimen
rilpivirin
emtricitabinetenofovir
df
rpvftctdf
efavirenzemtricitabinetenofovir
df
efvftctdf
rpv
taken
food
efv
taken
fast
openlabel
studi
primari
endpoint
proport
subject
rna
copi
ml
week
noninferior
margin
random
stratifi
rna
level
copiesml
copiesml
screen
analys
done
rna
level
data
present
week
trial
continu
week
full
detail
trial
design
primari
result
see
abstract
focu
report
give
key
outcom
result
includ
abstract
group
design
singletablet
rilpivirin
strpv
stefv
proport
patient
reach
primari
endpoint
hiv
rna
copiesml
strpv
stefv
respect
met
noninferior
criteria
virolog
failur
respect
drug
discontinu
respect
due
intoler
efv
patient
data
week
respect
treatment
proport
patient
achiev
hiv
control
decreas
increas
initi
viral
load
hiv
rna
copiesml
respect
similarli
virolog
failur
increas
respect
clearli
patient
maintain
hiv
control
viabl
resist
viru
virolog
resist
could
investig
patient
hiv
rna
least
copiesml
respect
viral
resist
detect
respect
mainli
patient
highest
initi
viral
load
number
patient
nervou
system
event
respect
overal
strpv
noninferior
stefv
efficaci
strpv
improv
toler
compar
stefv
came
cost
case
viral
resist
randal
lanier
chimerix
inc
durham
nc
usa
present
focus
viral
resist
studi
cell
cultur
sampl
clinic
trial
howev
randal
start
give
advanc
notic
adenoviru
preemptiv
therapi
trial
pediatr
adult
hematopoiet
stem
cell
transplant
hsct
patient
data
expect
avail
septemb
cell
cultur
studi
cmv
strain
resist
strain
detect
month
novel
mutant
gene
encod
cmv
polymeras
resist
remain
sensit
ganciclovir
gcv
foscarnet
fo
mutant
viru
appear
reduc
fit
cell
cultur
phase
ii
trial
patient
enrol
primarili
subject
use
mg
twice
weekli
mg
weekli
although
good
activ
obtain
two
higher
dose
given
twice
weekli
take
account
side
effect
mg
twice
weekli
optimum
dose
mg
dose
compar
placebo
therefor
good
trial
investig
select
resist
viru
due
underdos
none
sampl
n
contain
mutat
known
resist
mutat
polymorph
detect
patient
strain
retain
sensit
cidofovir
cdv
gcv
fo
trial
enrol
therapyexperienc
patient
n
lifethreaten
seriou
diseas
condit
caus
one
dsdna
virus
mani
patient
cmv
infect
known
gcvresist
mutat
gene
encod
kinas
activ
gcv
mutant
retain
sensit
discern
effect
respons
therapi
howev
patient
known
resist
mutat
cdv
reduc
respons
therapi
reduct
viral
load
mean
median
log
none
achiev
cmv
level
copiesml
contrast
patient
without
resist
mutat
mean
median
log
decreas
viral
load
mani
patient
cmv
level
copiesml
summari
prior
use
gcv
like
lead
resist
mutat
gene
cmv
compromis
subsequ
therapi
contrast
previou
therapi
cdv
dosag
may
limit
toxic
avoid
instead
use
patient
fail
gcv
therapi
introduct
molecular
forc
involv
drugtarget
bind
set
scene
minisymposium
three
differ
strategi
drug
discoveri
exemplifi
present
molecular
recognit
drug
design
daniel
dan
cheney
bristolmy
squibb
wallingford
ct
usa
describ
strength
hydrogen
bond
hbond
could
repres
energi
gain
valu
present
kcalmol
ga
phase
energi
gain
valu
neg
two
gener
consider
ligand
compet
water
receptor
hbond
need
order
latter
requir
may
mean
format
hbond
cost
reduc
entropi
protein
high
degre
flexibl
ie
high
entropi
hbond
rang
strong
bond
weaker
bond
much
stronger
doubl
bond
form
nh
group
attach
aromat
ring
halogen
bond
usual
rang
attach
electrondefici
ring
sever
type
interact
rang
pp
polar
van
der
waal
rapidli
emerg
field
research
kinet
bind
activ
drug
may
influenc
strength
bind
eg
ki
valu
length
time
drug
attach
protein
pocket
open
water
resid
time
may
short
protect
protein
pocket
better
shield
water
resid
time
may
longer
exampl
inhibitor
fatti
acid
synthesi
given
illustr
concept
fragmentbas
drug
discoveri
process
led
hcv
inhibitor
describ
susann
saalaubethel
astex
pharmaceut
dublin
ca
fit
well
target
site
bind
weak
eg
ic
lm
therefor
sensit
detect
system
nmr
requir
xray
crystallographi
often
use
confirm
candid
exampl
fragment
test
group
bind
tunnel
form
cterminu
hcv
helicas
bind
proteas
although
ec
valu
lm
fragment
identifi
hit
xray
crystallographi
essenti
aid
sar
studi
also
astexview
comput
program
give
chemist
view
ligandprotein
bind
found
use
four
compound
later
candid
activ
enough
ec
lm
test
replicon
system
obtain
resist
mutant
l
helicas
part
complex
seem
helicaseproteas
normal
open
activ
conform
inhibitor
keep
complex
close
inact
form
preclin
work
continu
complet
differ
approach
describ
john
kadow
bristolmy
squibb
wallingford
ct
usa
futur
therapi
hcv
genotyp
essenti
requir
overcom
hcv
resist
strategi
hit
viral
replic
hard
combin
inhibitor
phase
iia
trial
patient
tripl
therapi
gave
high
svr
phase
iii
trial
next
goal
nigel
liverton
merck
describ
convent
sar
studi
start
known
compound
led
vaniprevir
proteas
inhibitor
phase
ii
doserang
studi
patient
hcv
genotyp
vaniprevir
gave
impress
svr
week
respect
chemistri
minisymposium
prodrug
tool
drug
discoveri
develop
case
prodrug
alreadi
well
accept
within
antivir
field
probabl
mani
area
medicin
valentino
stella
univers
kansa
lawrenc
ks
usa
highlight
variou
factor
consid
slide
state
gi
tract
design
solvat
water
solubl
cyclohexan
solubl
may
guid
oral
absorpt
greasebal
molecul
administ
capsul
may
good
oral
bioavail
commonli
thought
increas
lipophil
decreas
water
solubl
studi
mani
drug
compar
water
solubl
lipophil
correl
coeffici
r
impli
factor
must
play
role
sometim
ad
highli
polar
group
help
exampl
ad
phosphat
amprenavir
fosamprenavir
gave
improv
water
solubl
phosphat
group
remov
enzymat
surfac
intestin
lipophil
parent
compound
easili
absorb
exampl
illustr
phosphat
stabl
may
give
water
solubl
may
increas
absorpt
highli
crystallin
high
meltingpoint
solid
much
lattic
energi
water
solvat
crystal
exampl
ad
ethyl
group
greatli
increas
water
solubl
reduc
lattic
energi
consid
prodrug
import
ensur
releas
moieti
harm
formaldehyd
often
seen
potenti
concern
speaker
refer
one
earlier
public
entitl
prodrug
releas
formaldehyd
concern
dhareshwar
stella
mani
drug
bioavail
rang
well
known
exampl
within
antivir
field
illustr
improv
valacyclovir
prodrug
acyclovir
work
well
improv
physic
properti
also
util
cellular
carrier
system
cidofovir
cdv
concentr
kidney
organ
anion
transport
lead
nephrotox
elion
award
lectur
icar
karl
hostetl
describ
tri
mimic
lysolecithin
order
util
lipid
transport
pathway
therebi
avoid
nephrotox
associ
cdv
randal
lanier
chimerix
inc
durham
nc
usa
gave
improv
properti
hexadecyloxypropylcdv
recent
clinic
result
pk
studi
confirm
essenti
cdv
plasma
dose
explain
lack
nephrotox
thought
monolipophil
chain
rather
bichain
allow
better
passag
cell
wall
molecul
flip
within
lipid
bilay
cdv
releas
within
cell
use
prodrug
intracellular
level
cdvdp
greater
cdv
current
expand
access
protocol
studi
n
patient
children
adult
either
adenoviru
adv
cmv
infect
dual
infect
adv
patient
respond
well
log
reduct
viral
load
may
reach
undetect
level
phase
ii
trial
cmv
patient
mg
twice
weekli
optimum
dose
treatment
start
cmv
dna
level
exceed
copiesml
patient
prior
mutant
strain
resist
cdv
respond
well
patient
howev
even
failur
case
viral
load
often
remain
copiesml
contrast
placebotr
patient
whose
viral
load
increas
well
copiesml
hiv
attach
inhibitor
low
water
solubl
partial
absorb
oral
auc
remain
virtual
unchang
dose
encourag
sundeep
valentino
paper
john
kadow
bristolmy
squibb
wallingford
ct
usa
report
use
phosphat
prodrug
pk
properti
much
improv
auc
much
higher
dose
respons
bioavail
unchang
food
howev
short
durat
plasma
concentr
ec
valu
less
h
radiocontrol
capsul
use
investig
effect
drug
releas
differ
part
intestin
tract
led
team
use
slowreleas
formul
prodrug
exampl
prodrug
formul
approach
use
togeth
amid
prodrug
tfv
evalu
potenti
replac
licens
tdf
richard
mackman
gilead
scienc
foster
citi
ca
usa
report
two
prodrug
taf
inform
taf
see
report
toma
cihlar
new
data
shown
phase
trial
pk
dose
mg
without
food
mg
food
investig
pbmc
level
activ
moieti
tfvdp
higher
respect
mg
dose
tdf
term
reduct
hiv
rna
mg
dose
compar
mg
dose
tdf
mike
sofia
oncor
biopharma
doylestown
pa
usa
gave
use
overview
nucleosid
nucleotid
prodrug
investig
treatment
hepat
c
advantag
activ
moieti
nucleotidetriphosph
analog
target
hcv
polymeras
highli
conserv
across
genotyp
prodrug
approach
use
extens
aid
oral
absorpt
also
use
take
advantag
transport
system
give
liver
target
nucleosid
analog
need
high
drug
level
greatest
progress
made
nucleotid
analog
sofosbuvir
mg
daili
day
gave
log
reduct
hcv
rna
level
combin
rbv
svr
even
better
combin
sofosbuvir
daclatasvir
inhibitor
gave
svr
sofosbuvir
combin
ledipasvir
inhibitor
singl
pill
start
phase
iii
trial
sofosbuvir
like
first
antihcv
nucleotid
analog
reach
marketplac
icar
demonstr
rapid
pace
progress
mani
area
antivir
research
perhap
recent
year
report
clinic
result
chemistryrel
topic
well
repres
imposs
record
hope
report
indic
rang
topic
cover
highlight
confer
undoubtedli
symposium
legaci
toni
first
two
speaker
erik
de
clercq
john
martin
closest
collabor
result
work
three
research
hivinfect
peopl
throughout
world
live
nearnorm
live
robert
schooley
robert
grant
henri
chan
richard
whitley
toma
cihlar
focuss
differ
area
inspir
toni
work
year
two
major
award
lectur
cover
differ
area
research
good
illustr
icar
strength
bring
differ
disciplin
togeth
keynot
address
plenari
lectur
clinic
symposium
minisymposia
gave
good
overview
progress
area
antivir
research
present
report
clinic
result
vital
part
icar
meet
beauti
research
scienc
need
lead
use
drug
clinic
symposium
prove
antivir
chemotherapi
continu
make
import
new
progress
although
area
progress
seem
vari
year
year
year
fewer
report
hbv
last
year
contrast
encourag
progress
hcv
therapi
maintain
prospect
first
nucleotid
analog
licens
time
next
icar
meet
combin
nucleotid
analog
inhibitor
look
set
transform
hcv
therapi
across
genotyp
hiv
singlepil
oncedaili
regimen
follow
quickli
establish
hcv
proteas
inhibitor
may
becom
littl
use
alway
drug
casualti
hcv
polymeras
inhibitor
progress
well
last
year
develop
stop
due
cardiotox
concern
relat
anoth
drug
similar
structur
new
approach
use
microrna
miravirsen
shown
encourag
posit
result
phase
ii
trial
updat
given
icar
decad
mainstay
hsv
vzv
therapi
acyclovir
prodrug
valaciclovir
famciclovir
last
year
encourag
report
herpesviru
helicaseprimas
inhibitor
updat
year
sinc
icar
clinicaltrialsgov
site
updat
statement
clinic
hold
due
nonclin
studi
valganciclovir
long
key
therapi
cmv
infect
continu
show
promis
phase
ii
trial
therapi
hivinfect
patient
alreadi
transform
introduct
singlepil
oncedaili
regiment
choic
regimen
expand
quad
becom
licens
drug
singlepil
regimen
progress
sever
year
icar
notabl
present
updat
progress
apricitabin
atc
clinic
trial
atc
show
except
barrier
hiv
resist
icar
meet
report
anoth
interest
nucleosid
analog
festinavir
good
activ
mani
resist
hiv
mutant
continu
develop
compound
seem
depend
econom
scientif
merit
great
strength
icar
potenti
crossfertil
differ
area
one
except
mani
divers
topic
notabl
shift
toward
includ
chemistri
minisymposia
chemic
flavor
would
like
add
thank
isar
offic
confer
committe
organ
anoth
interest
success
icar
